Gentium Withdraws NDA For Drug To Treat Stem Cell Transplant Complication
This article was originally published in The Pink Sheet Daily
Executive Summary
Italian biopharma's application for defibrotide is on hold while firm addresses FDA data quality and clinical trial oversight concerns.